We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
Bibliografía
[1]
Mahmood, T., Silverstone, T., Spittle, B., Rispendone appears to be safe in patients with antipsychotic-induced blood dyscrasias. Int Clin Psychopharmacol1996;11:53–4.CrossRefGoogle ScholarPubMed
[2]
Dernovsek, Z., Tavcar, R., Risperidone-induced leucopenia and nentropenia. Br J Psychiatry1997;171:393–4.CrossRefGoogle Scholar
[3]
Finkel, B., Lemer, A.G., Oyffe, I., Sigal, M., Risperidone-associated agranulocytosis. Am J Psychiatry1998;155:6.Google ScholarPubMed
[4]
Bondolfi, G., Morena, P., Dascal, D., Bertschy, G., Risperidone and reversible neutropenia: a negative rechallenge. Eur Neuropsychopharmacol1996;6:257.CrossRefGoogle ScholarPubMed
[5]
Hong, X., Wang, X., Agranulocytosis and neutropenia with typical and atypical neuroleptics. Am J Psychiatry2001;158:1736–7.CrossRefGoogle ScholarPubMed
[6]
Godleski, L.S., Semyak, MJ., Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry1996;153:735–6.Google ScholarPubMed